$ 203.94 <%= Resources.Global.txtUp %>
Updated 20/08/2019
Change % 0.38% Stock price increasing
Change 0.77 Stock price increasing
Volume 1,139,918
High $ 205.37
Low $ 203.58
Open $ 204.45
ISIN
Prev close $ 203.17
# of shares 599.70M
Market cap 122,303M USD
Intraday

Market closed
Amgen Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  203.94 2.3% Stock price increasing 15.9% Stock price increasing 19.1% Stock price increasing 8.8% Stock price increasing 3.1% Stock price increasing
Powered by TradingView

Related

Latest 1 week 1 month 3 months 6 months 1 year
YTD
 
Competitors Open
 
Abbott Laboratories 84.90 1.1% Stock price increasing -3.6% Stock price decreasing 11.3% Stock price increasing 11.5% Stock price increasing 29.3% Stock price increasing 17.4% Stock price increasing
 
Bristol-Myers Squibb Company 47.77 4.4% Stock price increasing 11.7% Stock price increasing 0.1% Stock price increasing -6.3% Stock price decreasing -21.1% Stock price decreasing -8.1% Stock price decreasing
 
Johnson & Johnson 131.53 0.8% Stock price increasing 2.2% Stock price increasing -5.2% Stock price decreasing -3.7% Stock price decreasing -2.3% Stock price decreasing 1.9% Stock price increasing
 
Eli Lilly and Company 111.46 1.1% Stock price increasing 3.9% Stock price increasing -5.5% Stock price decreasing -10.1% Stock price decreasing 6.1% Stock price increasing -3.7% Stock price decreasing
 
Merck & Company Inc (new) 86.91 4.1% Stock price increasing 7.0% Stock price increasing 7.3% Stock price increasing 7.6% Stock price increasing 25.9% Stock price increasing 13.7% Stock price increasing
 
Pfizer Inc 34.87 1.1% Stock price increasing -18.6% Stock price decreasing -17.0% Stock price decreasing -18.8% Stock price decreasing -17.1% Stock price decreasing -20.1% Stock price decreasing
 
Merck Kgaa O.N. 96.20 3.8% Stock price increasing 1.9% Stock price increasing 6.2% Stock price increasing 0.0% Stock price unchanged 4.5% Stock price increasing 6.9% Stock price increasing
 
Glaxosmithkline PLC ORD 25P 1,685.00 2.4% Stock price increasing 1.8% Stock price increasing 7.2% Stock price increasing 9.7% Stock price increasing 4.3% Stock price increasing 13.0% Stock price increasing
 
Takeda PHARM.CO.LTD. 30.04 0.1% Stock price increasing -1.4% Stock price decreasing -4.1% Stock price decreasing -14.2% Stock price decreasing -17.1% Stock price decreasing 3.8% Stock price increasing
 
Sanofi 77.93 4.1% Stock price increasing 3.3% Stock price increasing 4.0% Stock price increasing 7.4% Stock price increasing 4.2% Stock price increasing 3.0% Stock price increasing
 
Novartis N 88.56 2.4% Stock price increasing -4.3% Stock price decreasing 5.2% Stock price increasing 10.3% Stock price increasing 21.0% Stock price increasing 19.2% Stock price increasing
 
Roche GS 273.80 1.8% Stock price increasing 3.4% Stock price increasing 2.4% Stock price increasing -1.2% Stock price decreasing 13.4% Stock price increasing 12.5% Stock price increasing
 
Biogen Inc 233.18 2.4% Stock price increasing 0.3% Stock price increasing -0.8% Stock price decreasing -28.3% Stock price decreasing -32.4% Stock price decreasing -22.5% Stock price decreasing
 
Bayer AG NA O.N. 67.23 6.7% Stock price increasing 12.8% Stock price increasing 20.4% Stock price increasing 0.3% Stock price increasing -19.4% Stock price decreasing 11.0% Stock price increasing
 
Teva Pharmaceutical Industries.. 7.450 20.9% Stock price increasing -3.1% Stock price decreasing -35.4% Stock price decreasing -56.8% Stock price decreasing -70.4% Stock price decreasing -51.7% Stock price decreasing
 
Roche Holding AG Roche Holding.. 273.80 1.8% Stock price increasing 3.4% Stock price increasing 2.3% Stock price increasing -1.0% Stock price decreasing 13.2% Stock price increasing 13.5% Stock price increasing

Company profile

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).

Peers

Instruments Last Change  
Abbott Labor.. 84.90 0.4% Stock price increasing
Bristol-Myer.. 47.77 0.3% Stock price increasing
Johnson & Jo.. 131.53 0.7% Stock price increasing
Eli Lilly an.. 111.46 0.4% Stock price increasing
Merck & Comp.. 86.91 1.5% Stock price increasing
Pfizer Inc 34.87 0.8% Stock price increasing
Merck Kgaa O.. 96.20 0.8% Stock price increasing
Glaxosmithkl.. 1,685.00 1.1% Stock price increasing
Takeda PHARM.. 30.04 -2.0% Stock price decreasing
0,0,0,0,0,100,100,100,100,100
Sanofi 77.93 1.1% Stock price increasing
Novartis N 88.56 1.0% Stock price increasing
12,19,51,47,49,49,80,78,75,78
Roche GS 273.80 0.3% Stock price increasing
17,22,51,52,58,61,88,88,67,70
Biogen Inc 233.18 0.8% Stock price increasing
Bayer AG NA .. 67.23 1.9% Stock price increasing
Teva Pharmac.. 7.450 6.3% Stock price increasing
Roche Holdin.. 273.80 0.3% Stock price increasing

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 August 2019 00:10:24
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB1 - 2019-08-22 01:10:24 - 2019-08-22 00:10:24 - 1000 - Website: OKAY